Company profile for Silence Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA mole...
Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
United Kingdom
Address
Address
72 Hammersmith Road, London
Telephone
Telephone
+44 (0)20 3457 6900
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251112215352/en/Silence-Therapeutics-to-Participate-in-Fireside-Chat-at-Jefferies-Global-Healthcare-Conference

BUSINESSWIRE
12 Nov 2025

https://www.businesswire.com/news/home/20251106177990/en/Silence-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights

BUSINESSWIRE
06 Nov 2025

https://www.businesswire.com/news/home/20251023681567/en/Silence-Therapeutics-Completes-Enrollment-in-SANRECO-Phase-2-Study-of-Divesiran-for-Polycythemia-Vera-PV

BUSINESSWIRE
23 Oct 2025

https://www.businesswire.com/news/home/20250807436715/en/Silence-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Recent-Business-Highlights

BUSINESSWIRE
07 Aug 2025

https://www.businesswire.com/news/home/20250612873071/en/Silence-Therapeutics-Presents-Additional-Phase-1-Data-Highlighting-Promise-of-Divesiran-as-the-Potential-First-in-Class-siRNA-Treatment-for-Polycythemia-Vera

BUSINESSWIRE
12 Jun 2025

https://www.businesswire.com/news/home/20250508742900/en/Silence-Therapeutics-Reports-First-Quarter-2025-Financial-Results-and-Recent-Business-Highlights

BUSINESSWIRE
08 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty